Mutations that impair B lymphocyte death lead to immune disorders, including lymphadenopathy, splenomegaly and B cell lymphoma. cFLIP is a key cell death inhibitor whose elevated expression has been frequently associated with diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma (HL) and correlates with tumor progression and poor clinical outcome. However, the exact role of cFLIP in B-cell biology and lymphomagenesis has not been elucidated, yet. The major objective of this project is to characterize the role of cFLIP in the pathogenesis and progression of DLBCL and determine how its inhibition could be exploited for the treatment of lymphoma.
PRINCIPAL INVESTIGATOR
Laboratory of Cell Death, Inflammation and Immunity
CMMC - Center for Molecular Medicine Cologne
University of Cologne
Robert-Koch-Straße 21
50931 Cologne
Project Interactions
-
A01
Using autochthonous mouse models of aggressive lymphoma to systematically distill actionable vulnerabilities
Prof. Dr. med. Hans Christian Reinhardt -
A04
Role of apoptotic caspases in lymphomagenesis
Prof. Dr. rer. nat. Hamid Kashkar -
B01
LYN kinase as a key regulator in the microenvironmental niche of B cell lymphoid tumors
Prof. Dr. med. Michael Hallek, Dr. rer. nat. Phuong-Hien Nguyen